News

Following the launch of Herceptin SC in September 2013, MabThera SC is the second novel subcutaneous formulation of one of Roche’s oncology products using Halozyme’s patented EnhanzeTM (recombinant

The company’s Vice President of Sales Callum Baylis-Duffield said of the exemption, "As we gear up to commence marketing Phytofare in the coming quarter, qualifying for this exemption

The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer. Prostate cancer typically

"DTCC" stands for "The Depository Trust Clearing Corporation." DTCC is a member of the U.S. Federal Reserve System. It is a limited trust company under New York State

Tumor types were selected based on clinical observations in the phase 1 study and a detailed analysis of potential patient stratification biomarkers across tumor indications. The study will

The two programs, which issue from Affinium’s FabI discovery platform acquired by Debiopharm in February 2014, will lead to the development of narrow-spectrum antibiotics. As part of the

The trial is designed to further add to the clinical experience to date by showing the safety and tolerability of ZS-9 and its ability to restore and maintain

As part of the deal, PanAm seeks to distribute a minimum of 5,000 ‘cartons’ per month, or 150,000 pills per month, for the balance of the year with

Insys manufactures pharmaceutical dronabinol (THC) and pharmaceutical CBD at its FDA-inspected and Drug Enforcement Administration (DEA) approved facility in Round Rock, Texas. Recently, Insys submitted a drug master